Acute lymphocytic leukemia: Role of hematopoietic stem cell transplantation in current management

Irit Avivi*, Jacob M. Rowe

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Purpose of review: It is still unclear what the best postremission therapy is for young adults with acute lymphocytic leukemia (ALL). Encouraging results, supporting the superiority of allogeneic stem cell transplantation in CR1 compared with chemotherapy/allogeneic stem cell transplantation (ASCT), are coming from the ongoing international prospective MRC UKALL XII/ECOG 2993 study. However, the transplant-related morbidity and mortality remain high. Recent findings: The detection of persistent minimal residual disease (MRD) after induction and consolidation therapy is being increasingly used to identify high-risk patients for whom allogeneic transplant may offer the only curative option. Summary: The ultimate aim is to determine whether the absence of MRD pretransplant can be used as a surrogate for low-risk adult ALL that can be cured without allogeneic transplantation.

Original languageEnglish
Pages (from-to)463-468
Number of pages6
JournalCurrent Opinion in Hematology
Volume10
Issue number6
DOIs
StatePublished - Nov 2003
Externally publishedYes

Keywords

  • Acute lymphocytic leukemia
  • Allogeneic stem cell transplantation

Fingerprint

Dive into the research topics of 'Acute lymphocytic leukemia: Role of hematopoietic stem cell transplantation in current management'. Together they form a unique fingerprint.

Cite this